GSK-3858279 is commercialized by GSK, with a leading Phase II program in Osteoarthritis Pain. According to Globaldata, it is involved in 6 clinical trials, of which 2 were completed, 3 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of GSK-3858279’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for GSK-3858279 is expected to reach an annual total of $10 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
GSK-3858279 Overview
GSK-3858279 is under development for the treatment of osteoarthritis pain and diabetic neuropathic pain. It is formulated as a solution which is administered through intravenous and subcutaneous routes. It acts by targeting CCL17.
GSK Overview
GSK is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
For a complete picture of GSK-3858279’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.